Moxifloxacin pharmacokinetics, cardiac safety, and dosing for the treatment of rifampicin-resistant tuberculosis in children.

Kendra K RadtkeAnneke C HesselingJ L WincklerHeather R DraperBelen P SolansStephanie TheeLubbe WiesnerLouvina E van der LaanBarend FourieJames NielsenH Simon SchaafRadojka M SavicAnthony J Garcia-Prats

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)

Moxifloxacin doses above 10-15 mg/kg are likely required in young children to match adult exposures but require further safety assessment, especially when co-administered with other QT-prolonging agents.

Keyphrases

mycobacterium tuberculosis
pulmonary tuberculosis
young adults
air pollution
heart failure
emergency department
hepatitis c virus
adverse drug